Global Trust Asset Management LLC Has $1.45 Million Holdings in Cencora, Inc. (NYSE:COR)

Global Trust Asset Management LLC lowered its position in Cencora, Inc. (NYSE:COR) by 1.2% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 6,441 shares of the company’s stock after selling 80 shares during the period. Global Trust Asset Management LLC’s holdings in Cencora were worth $1,447,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Simon Quick Advisors LLC bought a new stake in shares of Cencora during the 4th quarter valued at about $211,000. Crossmark Global Holdings Inc. lifted its stake in Cencora by 6.3% in the fourth quarter. Crossmark Global Holdings Inc. now owns 39,462 shares of the company’s stock valued at $8,866,000 after buying an additional 2,351 shares during the period. Ballentine Partners LLC boosted its holdings in shares of Cencora by 4.1% during the 4th quarter. Ballentine Partners LLC now owns 8,880 shares of the company’s stock worth $1,995,000 after buying an additional 352 shares in the last quarter. UMB Bank n.a. grew its position in shares of Cencora by 10.6% during the 4th quarter. UMB Bank n.a. now owns 1,248 shares of the company’s stock worth $280,000 after buying an additional 120 shares during the period. Finally, Client 1ST Advisory Group LLC bought a new stake in shares of Cencora in the 4th quarter valued at $551,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on COR. Evercore ISI raised their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Barclays raised their target price on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Wells Fargo & Company dropped their price target on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research note on Friday, December 13th. Leerink Partners reduced their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research note on Monday, October 7th. Finally, Robert W. Baird boosted their price objective on Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $275.60.

Insider Activity

In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the sale, the chairman now owns 306,752 shares in the company, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock valued at $17,790,912 in the last 90 days. Insiders own 15.80% of the company’s stock.

Cencora Trading Up 1.3 %

Shares of COR stock opened at $245.21 on Wednesday. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $253.27. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company has a 50 day moving average of $237.38 and a 200-day moving average of $234.15. The firm has a market cap of $47.39 billion, a P/E ratio of 32.65, a PEG ratio of 1.51 and a beta of 0.49.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is a positive change from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. Cencora’s payout ratio is presently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.